6431.TW TAI
Kuangli Bio-Tech Holdings Co., Ltd.
1W: -2.3%
1M: -13.0%
3M: -13.0%
YTD: -34.7%
1Y: +8.6%
3Y: -11.7%
5Y: -49.3%
NT$16.90 ($0.53)
-0.15 (-0.88%)
Weekly Expected Move ±4.1%
NT$16
NT$16
NT$17
NT$18
NT$18
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$377M
-1.1% ▼
5Y CAGR: +19.8%
Gross Profit
$70M
+3.1% ▲
Operating Income
-$157M
-14.1% ▼
Net Income
-$193M
-11.7% ▼
EPS (Diluted)
$-2.07
+17.9% ▲
EBITDA
-$92M
-11.9% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $358M | $342M | $293M | $381M | $377M |
| YoY Growth | +134.5% | -4.5% | -14.3% | +30.0% | -1.1% |
| Cost of Revenue | $267M | $273M | $227M | $313M | $307M |
| Gross Profit | $92M | $69M | $66M | $68M | $70M |
| Gross Margin | 25.6% | 20.1% | 22.6% | 17.9% | 18.7% |
| R&D Expenses | $12M | $32M | $31M | $32M | $33M |
| SG&A Expenses | $94M | $125M | $150M | $174M | $186M |
| Operating Expenses | $106M | $157M | $180M | $206M | $228M |
| Operating Income | $65M | -$70M | -$114M | -$138M | -$157M |
| Operating Margin | 18.1% | -20.5% | -38.7% | -36.2% | -41.8% |
| Interest Expense | $8M | $14M | $14M | $16M | $14M |
| Income Before Tax | $61M | -$85M | -$124M | -$182M | -$193M |
| Tax Expense | $5M | -$14M | -$20M | -$10M | $0 |
| Net Income | $56M | -$71M | -$104M | -$173M | -$193M |
| Net Margin | 15.6% | -20.8% | -35.5% | -45.3% | -51.2% |
| EPS (Diluted) | $1.10 | $-1.26 | $-1.82 | $-2.52 | $-2.07 |
| EBITDA | $93M | -$9M | -$49M | -$83M | -$92M |
| Shares Outstanding | 51M | 56M | 57M | 69M | 93M |